Tough patient population in that trial. All must have ARDS and be on ventilators.

I know in the past I made a post about MESO pointing out I was surprised they did so well with their emergency use COVID patients considering that remestemcel-L had absolutely no effect in a COPD trial. MESO investors were not happy with me.